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Abstract
Introduction The public–private ADVANCE collaboration developed and tested a system to generate evidence on vaccine 
benefits and risks using European electronic healthcare databases. In the safety of vaccines, background incidence rates are 
key to allow proper monitoring and assessment. The goals of this study were to compute age-, sex-, and calendar-year strati-
fied incidence rates of nine autoimmune diseases in seven European healthcare databases from four countries and to assess 
validity by comparing with published data.
Methods Event rates were calculated for the following outcomes: acute disseminated encephalomyelitis, Bell’s palsy, Guil-
lain–Barré syndrome, immune thrombocytopenia purpura, Kawasaki disease, optic neuritis, narcolepsy, systemic lupus 
erythematosus, and transverse myelitis. Cases were identified by diagnosis codes. Participating organizations/databases 
originated from Denmark, Italy, Spain, and the UK. The source population comprised all persons registered, with at least 
1 year of data prior to the study start, or follow-up from birth. Stratified incidence rates were computed per database over 
the period 2003 to 2014.
Results Between 2003 and 2014, 148,947 incident cases of nine autoimmune diseases were identified. Crude incidence 
rates were highest for Bell’s palsy [23.8/100,000 person-years (PYs), 95% confidence interval (CI) 23.6–24.1] and lowest 
for Kawasaki disease (0.7/100,000 PYs, 95% CI 0.6–0.7). Specific patterns were observed by sex, age, calendar time, and 
data sources. Rates were comparable with published estimates.
Conclusion A range of autoimmune events could be identified in the ADVANCE system. Estimation of rates indicated con-
sistency across selected European healthcare databases, as well as consistency with US published data.
Key Points 
In the safety of vaccines, background incidence rates are 
key to allow proper monitoring and assessment.
Between 2003 and 2014, 148,947 new cases of nine 
autoimmune diseases were identified in seven European 
healthcare databases from four countries.
Incidence rates were highest for Bell’s palsy and lowest 
for Kawasaki disease. Specific patterns were observed by 
sex, age, calendar time, and data sources.
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1 Introduction
The Accelerated Development of VAccine beNefit-risk 
Collaboration in Europe (ADVANCE) was a public–pri-
vate consortium launched by the Innovative Medicines 
Initiatives in 2013 to bring together stakeholders (i.e. reg-
ulators, academics, and vaccine manufacturers) actively 
involved in the postmarketing monitoring of benefits and 
risks (B/R) of vaccines [1]. The aim of the ADVANCE 
project was to build an efficient system to generate robust 
evidence on background rates and vaccine coverage and, 
ultimately, to rapidly assess the B/R of vaccines using 
existing healthcare databases in Europe. ADVANCE has 
transitioned to the Vaccine Monitoring Collaboration for 
Europe that will implement the ecosystem [2]. In that 
context, several tools and methods have been developed 
to standardize ways of working among selected European 
healthcare databases. A description of the system and the 
methods/workflows can be found in the article by Sturk-
enboom et al. [1, 3].
With the entry of new vaccines to the market and their 
use on a large scale, rare adverse events not detected dur-
ing clinical development phases may occur. Large sample 
sizes are required to rapidly evaluate suspected causal 
associations between rare adverse events such as autoim-
mune diseases and vaccines in a real-world setting. Prepar-
edness to investigate safety signals and safety concerns is a 
necessary requirement of vaccination programs stipulated 
in the Vaccine Safety Blueprint [4]. Based on a stakeholder 
analysis in Europe, background rates are important from 
a regulatory, manufacturer, and public health perspective 
[1]. Because of the mode of action of vaccines and the fact 
that adjuvants, which stimulate immune response, may be 
used, autoimmune diseases are often events of interest to 
monitor and investigate. This is especially relevant consid-
ering that they have age-related patterns of onset that may 
coincide with age at vaccination. Moreover, autoimmune 
diseases are rare and because of the possible impact of 
environmental factors on their occurrence [5, 6], there is a 
constant need to generate up-to-date background incidence 
rates (IRs). As part of being prepared to respond to sig-
nals, background rates are a crucial source of information 
in the assessment of suspected cases, especially during 
mass vaccination campaigns [7] or for continuous safety 
monitoring of vaccines in a growing recipient population 
[8].
As part of the database characterization efforts of the 
ADVANCE project, we estimated background IRs of nine 
autoimmune diseases. We described and tried to explain 
heterogeneity among sources of data (e.g. hospital-based 
outcomes and/or primary care-based), and compared them 
with external published data [9].
2  Methods
2.1  Setting
The ADVANCE project had access to 20 different data 
sources, seven of which could be used in this assessment, 
representing four countries—Denmark, Spain, Italy, and the 
UK (Table 1). Detailed descriptions of these databases can 
be found in the electronic supplementary file.
All participating data sources extracted study data into a 
common data model (CDM). As described by Sturkenboom 
et al. [10], the CDM comprises three data files—population, 
events and vaccinations.
2.2  Population
The source population comprised all persons registered with 
at least 1 year of data prior to the start of the study period 
or follow-up from birth. Data for all individuals recorded in 
each database from the start of follow-up (defined as birth or 
first data availability, whichever was latest) until the end of 
follow-up (defined as the date at last data retrieval, leaving 
the database, the date of first event, or death, whichever date 
was earliest), were used to define the follow-up for database 
characterization. The only eligibility criteria were that the 
date of birth, start and end follow-up dates, and sex needed 
to be available. The study start date varied between data-
bases, depending on when the database collection started, 
and ended in 2017 for all databases. Data access providers 
(DAPs) created a population file in the format of the CDM 
including patient identifier, start of follow-up date, end of 
follow-up date, birth date, and sex.
2.3  Events
The autoimmune diseases of interest were acute dissemi-
nated encephalomyelitis (ADEM), Bell’s palsy, Guil-
lain–Barré syndrome (GBS), immune thrombocytopenia 
purpura (ITP), Kawasaki disease, optic neuritis, narcolepsy, 
systemic lupus erythematosus (SLE), and transverse myeli-
tis. The outcomes were defined using definitions from the 
Brighton Collaboration and learned societies, the World 
Health Organization, or the European Centre for Disease 
Prevention and Control. The case definitions were mapped 
to an initial list of the International Classification of Dis-
eases, Ninth Revision, Clinical Modification (ICD-9-CM), 
and ICD Tenth Revision (ICD-10), Read, and the Interna-
tional Classification of Primary Care (ICPC) codes using the 
ADVANCE Code mapper tool [11]. DAPs for each database 
were asked to modify and verify the proposed codes based 
on local coding habits and prior experience. Each DAP 
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extracted the final list of codes for the specific events in 
their local terminology and transformed the data into the 
event file of the CDM containing the following fields: patient 
identifier, event type, date, original code (ICD-9/10, Read, 
ICPC, or text). The event file was linked to the population 
file to calculate event IRs and to assess whether these rates 
were as expected by benchmarking rates within the data 
source, between data sources, and against published data. 
This assessment allowed us to demonstrate the appropriate-
ness of the data processing steps used. The code list for each 
outcome of interest is available in electronic supplementary 
Table S1. The ITP condition was defined according to nar-
row and broad concepts. Details on the harmonization pro-
cess for data extraction are described elsewhere [10].
2.4  Data Management and Analyses
The DAPs extracted data from their database using the local 
data format and software, which were transformed into the 
ADVANCE CDM (CSV format). We used Jerboa data 
processing software, which is JAVA-based, for event code 
counting and incidence calculations. The Jerboa software 
has been used for multiple studies and is freely available. 
The script and instructions were sent to the DAPs, who ran 
the script against their input files, and the outputs were sent 
through a secure file transfer protocol (File Zilla or High-
Tail) to a private remote research environment (PRRE) [10].
The event characterization included code counts by type 
of event and database, and event IRs in the population by cal-
endar year, sex, and age. Age was categorized per year until 
17 years, from 18–24 years, and then in 5-year categories. 
We subsequently categorized age in 0–1, 2–4, 5–14, 15–24, 
25–64, and ≥ 65 years for description, as this coincides with 
age of routine vaccination in general and because this cat-
egorization was compatible with the Post-licensure Rapid 
Immunization Safety Monitoring programme (PRISM) [9] 
US database age categories, allowing for age-specific com-
parisons of IRs between the US and European networks. 
For the incidence estimates calculated with Jerboa, there 
was a 1-year run-in period for individuals aged 6 months 
onward; individuals with an entry date within 6 months of 
birth started their follow-up at birth. Events recorded in 
the 1-year run-in prior to the start of follow-up were not 
considered and only first events recorded after the run-in 
period were considered to be incident. To have a compara-
ble period of calendar time across databases, IRs were lim-
ited to the calendar years 2003–2014. Healthcare databases 
were classified according to the type of data sources: gen-
eral practitioner databases including Base de Datos para la 
Investigación Farmacoepidemiológica en Atención Primaria 
(BIFAP), The Health Improvement Network (THIN), Royal 
College of General Practitioners (RCGP) Research and Sur-
veillance Centre (RSC), and Pedianet and hospitalization 
record linkage databases, including Aarhus University Hos-
pital (AUH)/Staten Serum Institute (SSI), Agenzia regionale 
di sanità (ARS), and Val Padana. We calculated crude IRs as 
the number of incident events within the follow-up period 
divided by the total person-time at risk and 95% confidence 
intervals (CIs) using the exact method for each event. IRs 
were expressed per 100,000 person-years (PYs). We also 
computed yearly pooled IRs for each autoimmune disease to 
compare the type of data sources (general practitioners vs. 
hospitalization record linkage) by using a random-effects 
model (Der Simonian–Laird method). Higgins I2 statistics 
were measured to determine heterogeneity between the type 
of data sources. Upon higher rates of narcolepsy observed 
in AUH/SSI, we conducted a post hoc analysis to estimate 
age-stratified IRs of narcolepsy in Denmark over the study 
period. Data handling and computation of rates were per-
formed in SAS 9.4 (SAS Institute Inc., Cary, NC, USA) and 
meta-analyses were conducted in Stata v14.0 (StataCorp 
LLC, College Station, TX, USA.
3  Results
Over the period 2003 to 2014, the total person-time of 
follow-up was more than 233 million PYs for the seven 
European healthcare databases. The largest contributions in 
follow-up were from AUH/SSI databases (30.9%), THIN 
(27.0%), and ARS (20.0%) (Table 2). The population aged 
between 15 and 64 years has most of the person-time rep-
resented in each database, except for Pedianet, which only 
captures the pediatric population. Between 2003 and 2014, 
there were 148,947 incident cases of nine predefined autoim-
mune diseases. Of the nine individual autoimmune diseases, 
the crude IR of Bell’s palsy was the highest (23.8/100,000 
PYs, 95% CI 23.6–24.1), followed by ITP broad definition 
(21.7/100,000 PYs, 95% CI 21.6–22.0), SLE (5.3/100,000 
PYs, 95% CI 5.2–5.4), ADEM (5.3/100,000 PYs, 95% CI 
5.2–5.3), ITP narrow definition (3.8/100,000 PYs, 95% CI 
3.7–3.9), optic neuritis (3.4/100,000 PYs, 95% CI 3.3–3.5), 
GBS (2.1/100,000 PYs, 95% CI 2.0–2.1), narcolepsy 
(1.1/100,000 PYs, 95% CI 1.0–1.1), transverse myelitis 
(1.0/100,000 PYs, 95% CI 0.9–1.0), and Kawasaki disease 
(0.7/100,000 PYs, 95% CIs 0.6–0.7). The sex-specific crude 
IRs of several autoimmune diseases were higher in females 
than in males (Table 3), and the most pronounced was SLE, 
with an IR of 8.5/100,000 PYs in females and 2.1/100,000 
PYs in males. For each database, age- and sex-specific crude 
IRs are presented in electronic supplementary Table S2.
3.1  Age‑Stratified Incidence Rates Per Database
Overall and age-stratified IRs are presented in Table 4. 
We observed that the age patterns differ across different 
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autoimmune diseases: IRs increased with increasing age for 
Bell’s palsy, GBS, and SLE. The narrow definition of ITP 
shows the highest rates in the 0–4 years age group. This 
rate decreased in children aged between 5 and 24 years, and 
increased by age from the age of 25 years. A similar pattern 
with a higher magnitude of rates was observed using the 
ITP broad definition. In the elderly (65 + years) IRs ranged 
between 22 and 64/100,000 PYs, except in BIFAP, where 
IRs peaked at 130/100,000 PYs. IRs for narcolepsy were low 
(≤ 1/100,000 PYs), but slightly higher rates were observed 
in the Danish database. In Denmark, the IR for narcolepsy 
was as high as 3.1/100,000 PYs in the 15–24 age group. A 
specific analysis of this age group per calendar year in the 
AUH/SSI database showed that IRs increased at the begin-
ning of the study period and tended to level out during the 
period 2008–2012, potentially followed by a slight increase 
towards the end of the study period (Fig. 1). The pattern of 
IRs for optic neuritis was similar across databases, increas-
ing by age and peaking in the 25–44 years age group, except 
in the BIFAP database, where a constant increase by age 
was observed. Although no clear pattern was observed for 
ADEM, IRs peaked in the 25–44 years age group in both 
Table 2  Follow-up duration and number of autoimmune events for each database over the period 2003–2014
AUH/SSI Aarhus University Hospital/Staten Serum Institute, BIFAP Base de Datos para la Investigación Farmacoepidemiológica en Aten-
ción Primaria, ARS Agenzia regionale di sanità, THIN The Health Improvement Network, RCGP RSC Royal College of General Practitioners 
Research and Surveillance Centre, ADEM acute disseminated encephalomyelitis, GBS Guillain–Barré syndrome, ITP immune thrombocytopenia 
purpura, SLE systemic lupus erythematosus
Denmark Italy Spain UK
AUH/SSI ARS Val Padana Pedianet BIFAP RCGP RSC THIN
Person-time (in years) per age groups and databases
Overall 71,963,997 46,690,197 4,429,415 414,725 29,654,858 16,845,082 63,107,306
0–1 years 1,630,983 784,016 78,040 82,862 696,022 438,305 1,572,725
2–4 years 2,495,269 1,152,313 116,835 110,105 888,063 571,917 2,127,038
5–14 years 9,224,436 3,910,548 404,509 221,758 2,721,747 1,916,302 7,140,915
15–24 years 10,413,928 3,951,513 382,907 – 4,936,428 1,945,611 6,908,561
25–44 years 19,350,418 13,002,241 1,177,745 – 9,343,807 4,601,269 17,333,183
45–64 years 17,953,083 12,977,224 1,247,063 – 6,829,082 4,454,574 17,064,552
65+ years 10,895,877 10,912,341 1,022,316 – 4,239,709 2,917,103 10,960,332
Total number of incident event databases for each autoimmune disease
Autoimmune diseases
ADEM 3866 5521 527 6 619 353 601
Bell’s palsy 14,087 2758 130 24 12,542 4194 18,398
GBS 1711 1085 109 < 5 321 257 1021
ITP (broad definition) 10,020 8970 474 11 14,796 3447 9923
ITP (narrow definition) 3775 872 63 7 484 639 2536
Kawasaki disease 412 420 12 30 47 123 407
Narcolepsy 1333 144 7 < 5 201 132 549
Optic neuritis 2982 1,048 72 < 5 694 533 2163
SLE 3526 1,438 151 < 5 1985 1078 3477
Transverse myelitis 678 144 12 < 5 < 5 213 783
Table 3  Crude incidence rates (/100,000 PYs) per sex for each auto-
immune disease
ADEM acute disseminated encephalomyelitis, GBS Guillain–Barré 
syndrome, ITP immune thrombocytopenia purpura, SLE systemic 
lupus erythematosus, PY person-years, IR incidence rate, CI confi-
dence interval
Autoimmune diseases IR (95% CI) per 100,000 PYs
Female Male
ADEM 6.14 (6.00–6.29) 4.31 (4.19–4.44)
Bell’s palsy 23.82 (23.54–24.11) 23.86 (23.57–24.15)
GBS 1.74 (1.66–1.82) 2.39 (2.30–2.48)
ITP (broad definition) 20.47 (20.20–20.73) 23.11 (22.83–23.40)
ITP (narrow definition) 3.95 (3.84–4.07) 3.69 (3.57–3.80)
Kawasaki disease 0.52 (0.47–0.56) 0.81 (0.76–0.87)
Narcolepsy 1.12 (1.06–1.19) 1.04 (0.98–1.10)
Optic neuritis 4.42 (4.29–4.54) 2.39 (2.29–2.48)
SLE 8.47 (8.30–8.65) 2.05 (1.97–2.14)
Transverse myelitis 1.10 (1.03–1.17) 0.83 (0.77–0.89)
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the record linkage Italian databases (ARS and ASCLR). 
The pattern of IRs for Kawasaki disease was similar across 
databases, with most of the events occurring before the age 
of 14 years. IRs for transverse myelitis varied from 0.0 to 
2.2/100,000 PYs; no events were reported in the BIFAP and 
Pedianet databases.
3.2  Incidence Rates Over Calendar Years According 
to the Type of Data Sources
Yearly pooled IRs of autoimmune diseases were stable over 
time but differed by type of data source for some diseases 
(electronic supplementary Fig. S1). IRs of ADEM and GBS 
were higher in hospital-based record linkage databases than 
in primary care databases. On the contrary, IRs of Bell’s 
palsy, ITP narrow, Kawasaki, SLE, and transverse myelitis 
were higher in primary care databases.
4  Discussion
In this study, we estimated age-, sex-, and calendar time-
specific background rates of nine autoimmune diseases of 
interest for vaccine safety assessment from seven European 
electronic healthcare databases. We demonstrated that the 
ADVANCE system could detect age-specific patterns and 
differences in IRs by the origin of information (e.g. hospital 
or general practioners) as well as sex. IRs were fairly stable 
over time for each disease, showing that identification or 
recording was not modified during the study period. The 
age-dependent patterns are important to know for the cal-
culation of observed versus expected cases, as some of the 
age categories in which rates increase coincide with the age 
of vaccination. The ADVANCE tools allowed for rapid esti-
mation of the rates by age, calendar time, and sex. Overall, 
IRs from the ADVANCE system were of a lower magnitude 
than rates generated through the US PRISM system, which 
covers claims-based diagnoses from outpatients, emergency 
units, and hospitalization. Age-specific patterns were simi-
lar for most of the autoimmune diseases, i.e. ADEM, Bell’s 
palsy, GBS, narcolepsy, optic neuritis, SLE, and transverse 
myelitis. IRs for ITP narrow definition matched rates from 
the US PRISM system more closely than those for the ITP 
broad definition. For both systems, PRISM and ADVANCE, 
we observed the highest rates for Kawasaki disease in chil-
dren < 4 years of age. The female predominance in SLE is 
also consistent with recent published literature [12], with the 
female:male ratio for SLE ranging from 4:1 to 9:1, which is 
aligned with our observation (4:1). In all databases, IRs for 
optic neuritis peaked between the ages of 25 and 44 years, 
decreasing thereafter, except in BIFAP, where we observed a 
constant increase by age. Estimates of the incidence of optic 
neuritis have been published from Barcelona [13], another 
region in Spain for which data are not captured in BIFAP. 
The data from Barcelona also confirmed the peak of IRs for 
optic neuritis in the 20–40 years age group over the period 
from 2008 to 2012. The reason for this variation in rates 
for optic neuritis between BIFAP and the other databases 
in ADVANCE is unknown. The ICPC code that was used 
is specific for optic neuritis, but this code may be used in 
clinical practice to code suspected conditions as a reason 
for referral to specialists allowing for testing, diagnosis and 
confirmation. IRs for narcolepsy were low and stable over 




























Fig. 1  Incidence rates for narcolepsy in the AUH/SSI database, per age group and calendar year. IR incidence rate, PY person-years, CI confi-
dence interval, AUH/SSI Aarhus University Hospital/Staten Serum Institute
Incidence of Autoimmune Diseases in European Healthcare Databases
of narcolepsy diagnosis was slightly elevated and showed 
periods with increases in persons between 15 and 24 years 
of age. However, an increase in the incidence of narcolepsy 
in Denmark was previously observed, and happened prior 
to the administration of the influenza A(H1N1)pdm09 pan-
demic vaccine, which has been associated with increases 
in the IR of narcolepsy in Finland, Norway, Ireland, and 
Sweden [14, 15], but not in countries with low vaccine cov-
erage [16].
Comparisons of our data with the US PRISM system 
showed similar age patterns in IRs [10]. Rates from PRISM, 
which is based on US claims data, were generally higher 
than the rates we observed in Europe. This may have several 
causes: coverage of outpatient specialist diagnoses, inclusion 
of prevalent cases, generally higher disease rates, or care-
seeking behavior. With regard to European published data, 
high similarities in rate patterns have been observed for most 
of the diseases, such as Bell’s palsy or GBS [7], Kawasaki 
disease [17, 18] or narcolepsy [16]. Nevertheless, no direct 
comparison could be made for several reasons: no overlap-
ping in age strata, ascertainment methods used, diverse 
sources of data, and their geographical location. Overall, 
this benchmark provides reassurance about external validity.
We demonstrated that all the participating databases 
provide crude rates consistent with expectations. However, 
our pooled crude rates should be interpreted with caution 
because they were not adjusted for any relevant covariates, 
nor were they weighted by the data sources with the largest 
person-time contribution, and should only be used in the 
context of each individual DAP’s results. Misclassification 
of incidence as prevalence may occur due to differences in 
health care provision, as some diagnoses are made in pri-
mary care whereas others may lead to hospitalization, and 
most of the databases do not capture all health care sites. 
Our analysis by type of data source highlights the specific 
process of diagnosis of autoimmune diseases. The quanti-
fication of these differences is important to realize when 
designing a specific study, and may profit from the compo-
nent strategy introduced in the ADVANCE project for this 
purpose [19]. Background rates of adverse events of special 
interest following immunization are always needed to con-
duct observed/expected analyses [7, 20], to understand bur-
den of disease of adverse events [21], or in cost-evaluation 
of vaccine implementation [22].
5  Conclusion
This study demonstrated that the European ADVANCE 
system can identify specific autoimmune events, that age-, 
sex- and time-specific rates can be generated based on avail-
able tools, and that the IRs are mostly consistent across 
selected European healthcare databases. Some variations 
were observed according to the type of care that is captured 
in the data sources.
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